ClinicalTrials.gg
TerminatedNCT01126216Paccis-RCTUpdated May 4, 2021

Reduced Radiotherapy With Pac/Cis vs Standard Radiotherapy With 5-FU/Cis in Locally Advanced Head and Neck Cancer

A Phase 3 interventional study of Paclitaxel/Cisplatin and Reduced RT in Head and Neck Cancer, sponsored by University of Erlangen-Nürnberg Medical School. Terminated at 13 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-04.

Sponsored by University of Erlangen-Nürnberg Medical School · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
After an Interims analysis the Data Safety Monitoring board recommended this because no significant difference between the two arms was seen and was not expected with an reasonable recruitment of patients. No interruptions of the trial were made.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
221
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 114 studies in Head and Neck Neoplasms with a site in Germany — 26 open to participants now, 38 under way, 9 of them phase 3. Head and Neck Neoplasms · Germany.

Enrollment
41st of 98
221 · median 167
Started
2010
with 1 other
Phase 3
26 of 114
3 open now
Registered
22nd of 114
by date
Lead sponsor
5 of 114
University of Erlangen-Nürnberg Medical School

Among the 114 studies in Head and Neck Neoplasms with a site in Germany, this one is the 41st largest by enrollment of the 98 interventional ones that give a count, is one of 2 that started in 2010, is one of 26 in phase 3, and was the 22nd registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

26 of the 114 studies in Head and Neck Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Head and Neck Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

Reduced RT with Pac/Cis vs. standard RCT with 5-FU/Cis

Read the detailed description

Standard treatment for patients with advanced, unresectable head and neck cancer is a platin-based simultaneous radiochemotherapy (RCT) (Pignon JP et al., Lancet 2000;355:949-955). However, irradiation dose is still debatable regarding local tumor control and late toxicity. Moreover, it is still unclear which combination of different drugs might be more effective.

In recent years, new drugs have been introduced in the field of head and neck cancer. The Taxanes, namely Docetaxel and Paclitaxel, have been investigated in several phase I/II-studies, and showed promising results concerning locoregional control rates and survival data. The RTOG 97-03 trial (Garden et al., J Clin Oncol 2004; 22:2856-64) compared a RCT either with Cisplatin/5-FU or Cisplatin/Paclitaxel. In this phase II-study an improvement of local tumor control and disease free survival of 15-20% in favour of the Cisplatin/Paclitaxel treatment arm was seen.

Therefore, our phase III-trial compares a standard RCT (70.6 Gy) with Cisplatin/5-FU to a RCT with Cisplatin/Paclitaxel and reduced irradiation dose (63.6 Gy). Primary endpoint is to proof superiority of the experimental Cisplatin/Paclitaxel treatment arm concerning disease-free-survival. Secondary endpoints are locoregional tumor control, overall survival and quality of life.

03

Conditions studied

  • Head and Neck Cancer

Keywords

  • Radiochemotherapy
  • head and neck cancer
  • Paclitaxel
  • Cisplatin
  • 5-FU
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven, locally advanced stage III-IV A-B (UICC 2002) primary squamous cell carcinoma of the oral cavity, the oropharynx, the hypopharynx, the supraglottic larynx
  • Age ≥ 18
  • Written for the participation in the clinical trial

Exclusion criteria

Exclusion Criteria:

  • Inadequate hepatic function: > 2,0 mg/dl, , SGPT, AP, Gamma-GT > 3 x
  • Inadequate bone marrow function: leukocytes \< 3,5 x 10\^9/l, \< 100 x 10\^9/l or neutrophils \< 1,5 x 10\^9/l
  • Serum creatinine > 1,5 mg/dl, \< 60ml/min
  • Uncontrolled severe somatic or psychological disease: e.g. unstable angina pectoris; myocardial infarction during the last 6 months; significant cardial rhythm disorders; apoplexy; high grade stenosis of the carotis; neurological or psychiatric disorders including convulsive disorders; dementia; psychosis; active uncontrolled infection or sepsis; liver cirrhosis; Child stage B,C; severe liver function disorders; marginal changes in the blood count; severe kidney damage; -infection
  • Acute infections
  • Fertile women without adequate during and up to 6 months after therapy (the method of contraception has to be high effective as described in the Note for guidance on non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals (CPMP/ICH/286/95 mod) and it has to be discussed with the investigator)
  • Pregnant or breast feeding women
  • Men, who are not willing to use adequate contraception during and up to 6 months after therapy, that is discussed with the investigator
  • -Status > 1
  • Reduced hearing function (especially higher frequencies)
  • Exsiccosis
  • Neuropathy, caused by cisplatin
  • Concurrent , with exception of adequately treated basal cell carcinoma of the skin or in situ carcinoma or the cervix
  • Prior radiotherapy of the neck or chemotherapy
  • Distant
  • Recurrent carcinoma in the head and neck region
  • Prior neck-dissection or surgical intervention exceeding an exploratory excision
  • Known intolerance to 5-Fluorouracil
  • Known deficit of Dihydropyrimidine dehydrogenase (DPD)
  • Simultaneous therapy with Brivudin or other inhibitors of DPD
  • Known intolerance to Cisplatin or other substances that contain platin
  • Known intolerance to Paclitaxel or one of the included substances, especially to Poly(oxyethylene)Rhizinusöl/Macrogolglycerol ricinoleate
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
221 participants (actual)

Study arms

  • Experimental
    Reduced RT + Pacitaxel/Cisplatin

    63,6 Gy accelerated hyperfractionated radiotherapy with Paclitaxel (20mg/m\^2/d) on days 2, 5, 8, 11 and 25, 30, 33, 36) and Cisplatin (20mg/m\^2/d) on days 1-4 and 29-32, followed by a salvage operation or neck dissection if there is persisting tumor

    Drug: Paclitaxel/Cisplatin · Radiation: Reduced RT

  • Active comparator
    Standard RT + 5-Fluorouracil/Cisplatin

    70,6 Gy accelerated hyperfractionated radiotherapy with 5-Fluorouracil(600mg/m\^2/d) on days 1-5 and 29-33) and Cisplatin (20mg/m\^2/d) on days 1-5 and 29-33, followed by a salvage operation or neck dissection if there is persisting tumor

    Drug: 5-FU/Cisplatin · Radiation: Standard RT

Interventions

  • DrugPaclitaxel/Cisplatin

    Drug page: TP protocolStudies of TP protocolTP protocol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Experimental: Paclitaxel (20mg/m\^2/d) on days 2, 5, 8, 11 and 25, 30, 33, 36) and Cisplatin (20mg/m\^2/d) on days 1-4 and 29-32,

  • RadiationReduced RT

    Experimental: 63,6 Gy accelerated hyperfractionated radiotherapy

  • Drug5-FU/Cisplatin

    Drug pages: FluorouracilStudies of FluorouracilFluorouracil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Active Comparator: 5-Fluorouracil(600mg/m\^2/d) on days 1-5 and 29-33) and Cisplatin (20mg/m\^2/d) on days 1-5 and 29-33

  • RadiationStandard RT

    Active Comparator: 70,6 Gy accelerated hyperfractionated radiotherapy

06

What researchers measure

Primary outcomes

  1. Disease free survival

    Time frame: 3 years

Secondary outcomes

  1. Overall Survival

    Time frame: 3 years

  2. Distant metastasis free survival

    Time frame: 3 years

  3. Local control

    Time frame: 3 years

  4. Acute and Late Toxicity

    Time frame: 4 years

  5. Life Quality

    Time frame: 4 years

  6. HPV/p16-Status

    Time frame: End of study

07

Study locations

13 sites
  • Klinikum Coburg, Strahlentherapie, DiaCura
    Coburg, 96450, Germany
  • Universitätsklinikum Düsseldorf, Klinik und Poliklinik für Strahlentherapie und Radiologische Onkologie
    Düsseldorf, 40225, Germany
  • Universitätsklinikum Erlangen, Strahlenklinik
    Erlangen, 91054, Germany
  • Universitätsklinikum Frankfurt, Klinik für Strahlentherapie und Radioonkologie
    Frankfurt/M., 60590, Germany
  • Klinikum am Eichert, Praxis für Strahlentherapie und Klinik für Radioonkologie
    Göppingen, 73035, Germany
  • Universitätsklinikum des Saarlandes, Klinik für Strahlentherapie und Radioonkologie,
    Homburg/Saar, 66421, Germany
  • Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Klinik und Poliklinik für Hals-Nasen- und Ohrenkranke
    Lübeck, 23538, Germany
  • Kliniken Maria Hilf GmbH Mönchengladbach, Klinik für Strahlentherapie
    Mönchengladbach, 41063, Germany
  • Klinikum München Pasing und Perlach, Klinik für HNO
    München, 81241, Germany
  • Brüderkrankenhaus st. Josef Paderborn, Klinik für Strahlentherapie
    Paderborn, 33098, Germany
  • Universitätsklinikum Regensburg, Klinik und Poliklinik für Strahlentherapie
    Regensburg, 93053, Germany
  • Klinikum St. Elisabeth Straubing, Klinik für Hals-Nasen-Ohren-Heilkunde
    Straubing, 94315, Germany
  • MVZ am Klinikum Mutterhaus der Borrmäerinnen, Strahlentherapie
    Trier, 54290, Germany
08

References and documents

Publications

  • Fietkau R, Hecht M, Hofner B, Lubgan D, Iro H, Gefeller O, Rodel C, Hautmann MG, Kolbl O, Salay A, Rube C, Melchior P, Breinl P, Krings W, Gripp S, Wollenberg B, Keerl R, Schreck U, Siekmeyer B, Grabenbauer GG, Balermpas P; PacCis-Study Group. Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard radiotherapy with fluorouracil/cisplatin: The PacCis-trial. Radiother Oncol. 2020 Mar;144:209-217. doi: 10.1016/j.radonc.2020.01.016. Epub 2020 Feb 7. PubMed 32044419 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2010 to primary completion in Jun 2015, 60 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2010
First posted
May 19, 2010
StartActual
Jun 2010
Primary completionActual
Jun 2015
CompletionActual
Jun 2019
Last update
May 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01126216
Collaborators
Deutsche Krebshilfe e.V., Bonn (Germany)
Responsible party
Sponsor
First posted
May 19, 2010
Start date
Jun 2010
Primary completion
Jun 2015
Completion
Jun 2019
Last update
May 4, 2021

Study contacts

Rainer Fietkau, MD
study director · Strahlenklinik, Universitätsklinikum Erlangen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TP protocol

Start the discussion